<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CHOLINE SALICYLATE</span><br/>(koe'leen)<br/><span class="topboxtradename">Arthropan<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">analgesic, salicylate</span>; <span class="classification">antipyretic</span><br/><b>Prototype: </b>Aspirin<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>870 mg/5 mL liquid</p>
<h1><a name="action">Actions</a></h1>
<p>Choline salt of salicylic acid available commercially as a liquid preparation which is a nonsteroidal antiinflammatory agent.
         Mode of action is by inhibiting prostaglandin synthesis.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Reported to be less potent than aspirin as an analgesic, antiinflammatory, and antipyretic, and produces less gastric irritation
         and bleeding. Unlike aspirin, believed to have no appreciable effect on platelet function.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Analgesic and antiinflammatory in rheumatoid arthritis, rheumatic fever, osteoarthritis, and other conditions for which oral
         salicylates are usually recommended. May be indicated for patients who have difficulty swallowing tablets or capsules or as
         an alternative preparation for patients who show gastric intolerance to aspirin or who should avoid sodium-containing salicylates.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Salicylate hypersensitivity; children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Chronic renal and hepatic failure, peptic ulcer; patients on coumadin or heparin; lactation; older adults.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Analgesic, Antipyretic</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 435870 mg (2.55 mL) q4h<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>211 y:</i> 50 mg/kg/d<br/><br/><span class="indicationtitle">Arthritis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 4.87.2 g (2841 mL)/d in 46 divided doses<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 107134 mg (0.60.8 mL)/kg/d in 46 divided doses<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>May be mixed with or followed by fruit juice, a carbonated beverage, or water. Do not administer with an antacid.</li>
<li>If patient requires an antacid, administer choline salicylate before meals and the antacid 2 h after meals.</li>
<li>Store in tightly capped container at temperature between 15° and 30° C (59° and 86° F). Protect from freezing.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> GI:</span>
<span class="speceff-common">Nausea,</span> vomiting, hepatotoxicity. <span class="typehead">CNS:</span> Dizziness, sweating, mental confusion, hyperventilation. <span class="typehead">Special Senses:</span> Tinnitus, deafness. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>As for aspirin with the exception of <span class="alt">5-HIAA</span> which is not affected by choline salicylate.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Aminosalicylate</b> increases risk of salicylate toxicity; increases risk of bleeding with <span class="classification">oral anticoagulants</span>; <span class="classification">sulfonylureas</span> pose increased risk of hypoglycemia with large doses of salicylates; <span class="classification">carbonic anhydrase inhibitors</span> cause metabolic acidosis that may increase salicylate toxicity; <span class="classification">corticosteroids</span> add to ulcerogenic effects; may increase <b>methotrexate</b> levels; small doses of salicylates may blunt uricosuric effects of <b>probenecid,</b>
<b>sulfinpyrazone.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> 1030 min. <span class="typehead"> Distribution:</span> Widely distributed in most body tissues; crosses placenta; distributed in breast milk. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 23 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor effectiveness of drug in relieving pain in arthritic joints.</li>
<li>Assess for signs of bleeding, especially in patients on anticoagulant therapy.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report any of the following to physician: tinnitus, persistent gastric irritation, epigastric pain, unexplained bruising or
            bleeding.
         </li>
<li>This drug is available OTC. Do not exceed recommended dosage and keep medicine out of the reach of children.</li>
<li>Avoid concurrent use of other drugs containing aspirin or salicylates unless otherwise advised by physician.</li>
<li>Do not breast feed without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>